K. Lentz

D. Barends, R. A. Lipper, V. Shah, 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.

C. Chu, E. A. Brown, D. Gordon, 2022, Cell metabolism.

Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.

Vijay T. Ahuja, J. Macor, T. Molski, 2016, Bioorganic & medicinal chemistry letters.

Linking (Pyr)1apelin-13 pharmacokinetics to efficacy: Stabilization and measurement of a high clearance peptide in rodents.

Michael C. Myers, Rongan Zhang, P. Gargalovic, 2019, Analytical biochemistry.

A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Vijay T. Ahuja, J. Macor, Y. Shu, 2009, Journal of medicinal chemistry.

A Quantitative Structure-Property Relationship for Predicting Drug Solubility in PEG 400/Water Cosolvent Systems

Feng Qian, Srini Venkatesh, Xue-Qing Chen, 2004, Pharmaceutical Research.

Current Methods for Predicting Human Food Effect

Kimberley A. Lentz, K. Lentz, 2008, The AAPS Journal.

Aqueous and cosolvent solubility data for drug-like organic compounds

S. Venkatesh, E. Rytting, Xue-Qing Chen, 2005, The AAPS Journal.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Alan G. E. Wilson, G. Shankar, S. Mandlekar, 2016, The Journal of Pharmacology and Experimental Therapeutics.

The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers

H. Soares, J. Macor, R. Berman, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Macrocyclic prolinyl acyl guanidines as inhibitors of β-secretase (BACE).

A. Good, J. Macor, C. Albright, 2015, Bioorganic & medicinal chemistry letters.

Development and validation of a preclinical food effect model.

P. Marathe, D. G. Morgan, C. Gleason, 2007, Journal of pharmaceutical sciences.

Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system.

J. Polli, J. Hayashi, K. Lentz, 2000, International journal of pharmaceutics.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

J. Macor, M. Ahlijanian, Joseph L. Cantone, 2014, International journal of Alzheimer's disease.

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

H. Feldman, J. Macor, R. Berman, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Structure activity relationship studies of 3-arylsulfonyl-pyrido[1,2-a]pyrimidin-4-imines as potent 5-HT₆ antagonists.

D. Langley, R. Westphal, P. Sivaprakasam, 2014, Bioorganic & medicinal chemistry.

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.

J. Macor, C. Albright, R. Olson, 2010, ACS medicinal chemistry letters.

Role of regional absorption and gastrointestinal motility on variability in oral absorption of a model drug

A. Narang, Anand Balakrishnan, Jennifer J Wang, 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Increased acyclovir oral bioavailability via a bile acid conjugate.

J. Polli, A. Coop, D. Maeda, 2004, Molecular pharmaceutics.

Drug Metabolism and Pharmacokinetics in Drug Discovery

J. Raybon, M. Sinz, K. Lentz, 2013 .

Discovery of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of pain

A. Good, J. Macor, L. Bristow, 2023, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents.

P2-346: PGP efflux and other factors limit brain Aβ reduction by BACE1 inhibitors in mice

J. Macor, J. Marcinkeviciene, M. Ford, 2008, Alzheimer's & Dementia.

Influence of Passive Permeability on Apparent P-glycoprotein Kinetics

James E. Polli, Stephen A. Wring, Joseph W. Polli, 2000, Pharmaceutical Research.

Phenacetin Pharmacokinetics in CYP1A2-Deficient Beagle Dogs

M. Sinz, Daniel G Morgan, K. Lentz, 2012, Drug Metabolism and Disposition.

JPET # 199356 3 Recommended section assignment to guide listing in table of contents : Neuropharmacology

H. Feldman, J. Macor, R. Berman, 2012 .

Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE).

A. Good, J. Macor, J. Marcinkeviciene, 2011, Bioorganic & medicinal chemistry letters.

Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis.

Ramesh Padmanabha, A. Good, J. Macor, 2012, Journal of medicinal chemistry.

Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1.

J. Macor, J. Marcinkeviciene, P. Morin, 2011, Bioorganic & medicinal chemistry letters.

Inhibition of AAK 1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain s

Alan G. E. Wilson, Malley, G. Shankar, 2016 .

Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Joseph Payne, Vijay T. Ahuja, Yue-Zhong Shu, 2009, Journal of medicinal chemistry.

Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.

J. Macor, R. Schartman, G. Dubowchik, 2012, ACS medicinal chemistry letters.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.

Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs

R. Kona, R. Fahmy, S. Hoag, 2017, The AAPS Journal.

Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.

A. Mathur, E. Priestley, J. M. Richter, 2024, Journal of medicinal chemistry.